Yann Seimbille

Yann Seimbille is an Associate Professor at Erasmus MC, affiliated with the Radiology & Nuclear Medicine department and school. His work focuses on radiochemistry, theranostic agents, and targeted radionuclide therapies for cancers like neuroendocrine tumors. He has contributed to over 147 research outputs, including peer-reviewed articles and conference abstracts.

Key research interests include Actinium-225 applications, somatostatin receptor ligands, and developing novel radiopharmaceuticals. He collaborates internationally on radionuclide therapy comparisons (e.g., Tb-161 vs Lu-177) and theranostic drug conjugates like eSOMA-DM1.

Recent studies (2024-2025) highlight advancements in radiochemical synthesis, quality control protocols, and preclinical evaluations of radiolabeled compounds. His work has been featured in journals such as EJNMMI Radiopharmacy and Chemistry and Bioconjugate Chemistry.

He has supervised 3 academic works and his research is cited in patents and widely read on platforms like Mendeley. Collaborations span institutions globally, emphasizing interdisciplinary approaches to nuclear medicine advancements.